Radiation recall dermatitis induced by trastuzumab
Dochang Moon1, Ja Seung Koo2, Chang-Ok Suh3
1Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea.
Breast Cancer (Tokyo, Japan)
|April 2, 2013
Summary
This case study highlights a rare instance of radiation recall dermatitis triggered by trastuzumab in a breast cancer patient. The condition manifested as a fever and rash in previously irradiated skin following trastuzumab monotherapy.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- A 55-year-old woman with metastatic breast cancer received trastuzumab/paclitaxel chemotherapy.
- She underwent surgery and locoregional radiotherapy.
- Trastuzumab monotherapy was initiated post-radiotherapy.
Observation:
- Dermatitis developed in previously irradiated skin nine days after the fifth cycle of trastuzumab monotherapy.
- The patient experienced a high fever and skin rash.
- This reaction occurred during trastuzumab monotherapy after completion of radiotherapy.
Findings:
- The patient developed radiation recall dermatitis.
- Trastuzumab was identified as the likely trigger for this rare adverse event.
- This represents a potential first reported case of trastuzumab-induced radiation recall dermatitis.
Implications:
- Clinicians should be aware of the possibility of trastuzumab-induced radiation recall dermatitis.
- Prompt recognition and management are crucial for patients receiving trastuzumab after radiotherapy.
- Further investigation may be warranted to understand the mechanism and incidence of this rare side effect.
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...